Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable
Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical
Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma
WORCESTER, Mass.--(BUSINESS WIRE)--Jun 28, 2007 - BiovestInternational, Inc. (OTCBB: BVTI), a majority owned subsidiary ofAccentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), announced on June27, 2007
blinded interim data from the start of its fast-trackedpivotal Phase 3 clinical trial of BiovaxID(TM) for Non-Hodgkin'slymphoma (NHL) from September 2000 through June 2006. This interim
blinded dat...
Accentia Biopharmaceuticals Announces Favorable Interim Blinded
Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial
for Chronic Sinusitis
TAMPA, Fla.--(BUSINESS WIRE)--Jun 28, 2007 - AccentiaBiopharmaceuticals, Inc. (NASDAQ: ABPI) announced on Wednesday,June 27 at the Jefferies Healthcare Conference that its interimanalysis of the
blinded data on the first fifty patients in theFast-Tracked Phase 3 clinical study of SinuNase(TM), at 8 weekspost-randomization, has demonstrated substantial improvement inresolution of one or both...